| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
FKGK18 manufacturers
- FKGK 18
-
- $429.00
-
2026-04-21
- CAS:1071001-09-6
- Purity:
- Supply Ability: 10g
|
| Product Name: | FKGK18 | | Synonyms: | FKGK18;FKGK18
(FKGK 18);1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one;2-Hexanone, 1,1,1-trifluoro-6-(2-naphthalenyl)-;1,1,1-trifluoro-6-(2-naphthalenyl)-2-hexanone | | CAS: | 1071001-09-6 | | MF: | C16H15F3O | | MW: | 280.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1071001-09-6.mol |  |
| | FKGK18 Chemical Properties |
| Boiling point | 382.5±42.0 °C(Predicted) | | density | 1.188±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; PBS (pH 7.2): 2 mg/ml | | form | A crystalline solid | | color | Light yellow to yellow |
| | FKGK18 Usage And Synthesis |
| Uses | FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes[1][2][3]. | | in vivo | FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence[3]. | Animal Model: | 10-day-old female NOD mice[3] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia | | Result: | Reduced diabetes incidence and maintained better glucose homeostasis. |
| | References | [1] Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DOI:10.1021/jm901872v
[2] Ali T, et al. Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetes. PLoS One. 2013 Aug 20;8(8):e71748. DOI:10.1371/journal.pone.0071748
[3] Bone RN, et al. Inhibition of Ca2+-independent phospholipase A2β (iPLA2β) ameliorates islet infiltration and incidence of diabetes in NOD mice. Diabetes. 2015 Feb;64(2):541-54. DOI:10.2337/db14-0097 |
| | FKGK18 Preparation Products And Raw materials |
|